SAB Biotherapeutics to Present at Chardan Healthcare Conference…

Event summary

SAB Biotherapeutics to participate in Chardan 10th Annual Healthcare Conference on October 20, 2026.
CEO Samuel J. Reich to lead a fireside chat from 11:15 - 11:30 a.m. ET.
Management available for one-on-one meetings during the conference.
Company developing hATG for type 1 diabetes and other autoimmune diseases.
Lead candidate SAB-142 in Phase 2b clinical trial for type 1 diabetes.

The big picture

SAB Biotherapeutics' participation in the Chardan Healthcare Conference comes at a critical juncture for its lead candidate, SAB-142, which is currently in a registrational Phase 2b trial. The company's proprietary technology, leveraging transchromosomic cattle to produce human immunoglobulins, positions it uniquely in the autoimmune disease space. Success in this trial could validate its platform and attract further investment, while failure may necessitate a strategic pivot.

What we're watching

Clinical Progress: The pace at which SAB-142 advances through the Phase 2b trial will determine its regulatory pathway and commercial potential.
Investor Sentiment: How the fireside chat and one-on-one meetings impact investor confidence in SAB Biotherapeutics' long-term strategy.
Competitive Positioning: Whether SAB Biotherapeutics can differentiate its hATG technology in a crowded autoimmune disease market.